We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Venlafaxine Extended Release (XR) for the Prophylaxis of Migraine and Tension-type Headache: A Retrospective Study in a Clinical Setting.
- Authors
Adelman, Leon C.; Adelman, James U.; Von Seggern, Randal; Mannix, Lisa K.
- Abstract
Objective.—To assess the efficacy of extended-release venlafaxine in the prophylaxis of migraine and chronic tension-type headache. Background.—Venlafaxine, a structurally novel antidepressant, is a selective serotonin-norepinephrine reuptake inhibitor. This study is the first to test the effects of extended-release venlafaxine on headaches. Methods.—Patients were evaluated on a retrospective basis. Fifty-six patients with chronic tension-type headache and 114 patients with migraine were prescribed extended-release venlafaxine. Nearly all the study subjects had been resistant to several previous preventive medications. Patients took venlafaxine for an average of 6 months with a median dose of 150 mg (range, 37.5 to 300 mg). Results.—The mean frequency of headaches in the group with chronic tension-type headache fell from 24.0 to 15.2 per month (P < .0001). The group with migraine showed a reduction from 16.1 to 11.1 headaches per month (P < .0001). The medicine was well tolerated. Conclusions.—This trial indicates that extended-release venlafaxine has potential in headache prophylaxis based on its efficacy and safety profile. We recommend a double-blind, placebo-controlled study to further assess the role of extended-release venlafaxine in headache prevention.
- Subjects
VENLAFAXINE; MIGRAINE; TENSION headache; CHEMOPREVENTION; DRUG efficacy
- Publication
Headache: The Journal of Head & Face Pain, 2000, Vol 40, Issue 7, p572
- ISSN
0017-8748
- Publication type
Article
- DOI
10.1046/j.1526-4610.2000.00089.x